文献速递腹部技术与安全PETCT

18F-FDG PET/CT对围手术期FLOT化疗胃食管癌患者治疗反应及无进展生存期的预后价值

Prognostic value of [18F]FDG PET/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapy.
PubMed 文献 · Eur J Radiol · 2023-04-20

本文为单中心回顾性研究,纳入31例接受围手术期FLOT化疗的胃或胃食管结合部腺癌患者,于化疗前及化疗后(17/31例)行18F-FDG PET/CT,提取原发肿瘤代谢参数。结果显示化疗前SULpeak与病理反应显著相关,化疗后代谢参数(SUVmax、SUVmean、SULpeak、SULmean)及分期与PFS显著相关。提示PET/CT代谢参数有助于预测FLOT化疗反应及预后。

要点

  • 化疗前SULpeak可预测GC/GEJAC对FLOT新辅助化疗的病理反应。
  • 化疗后PET/CT的SUVmax、SUVmean、SULpeak、SULmean与PFS显著相关。
  • 分期相关因素亦与PFS显著相关,提示治疗前分期评估的重要性。
英文原文(摘要)· 点击展开

PURPOSE: To evaluate the prognostic role of [18F]FDG PET/CT metabolic parameters in gastric cancer (GC) and gastroesophageal adenocarcinoma (GEJAC) patients receiving neoadjuvant chemotherapy.

METHOD: In this retrospective study, 31 patients with biopsy-proven GC or GEJAC were included between August 2016 and March 2020. [18F]FDG PET/CT was performed before the neoadjuvant chemotherapy. Primary tumours' semi-quantitative metabolic parameters were extracted. All patients received a perioperative FLOT regimen thereafter. Post-chemotherapy [18F]FDG PET/CT was performed in most patients (17/31). All patients underwent surgical resection. Histopathology response to treatment and progression-free survival (PFS) were evaluated. Two-sided p-values < 0.05 were considered statistically significant.

RESULTS: Thirty-one patients (mean age = 62 ± 8), including 21 GC and 10 GEJAC patients, were evaluated. 20/31(65%) patients were histopathology responders to neoadjuvant chemotherapy, including twelve complete and eight partial responders. During the median follow-up of 42.0 months, nine patients experienced recurrence. The median PFS was 60(95% CI:32.9-87.1) months. Pre-neoadjuvant chemotherapy SULpeak was significantly correlated with pathological response to treatment (p-value = 0.03;odds ratio = 16.75). In survival analysis, SUVmax (p-value = 0.01;hazard ratio[HR] = 1.55), SUVmean (p-value = 0.04;HR = 2.73), SULpeak (p-value < 0.001;HR = 1.91) and SULmean (p-value = 0.04;HR = 4.22) in the post-neoadjuvant chemotherapy pre-operative [18F]FDG PET/CT showed significant correlation with PFS. Additionally, aspects of staging were significantly correlated with PFS (p-value = 0.01;HR = 2.21).

CONCLUSIONS: Pre-neoadjuvant chemotherapy [18F]FDG PET/CT parameters, especially SULpeak, could predict the pathological response to treatment in GC and GEJAC patients. Additionally, in survival analysis, post-chemotherapy metabolic parameters significantly correlated with PFS. Thus, performing [18F]FDG PET/CT before chemotherapy may help to identify patients at risk for inadequate response to perioperative FLOT and, after chemotherapy, may predict clinical outcomes.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Mirshahvalad, Seyedinia, Huemer, et al. Prognostic value of [18F]FDG PET/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapy. Eur J Radiol. 2023. PMID: 37119707. doi:10.1016/j.ejrad.2023.110843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。